Catalent (CTLT) and Novo Nordisk's (NVO) parent company Novo Holdings said Monday that they have completed all regulatory closing conditions for Novo's pending acquisition of Catalent.
The deal to take Catalent private under Novo is now expected to close in the coming days, the companies said.